VRXA: Veraxa Biotech AG - Post de-SPAC insider trading, 5% holders and institutional ownership
From public SEC filings: open-market insider purchases and sales (Form 4, last 180 days), holders of 5% or more (Schedules 13D and 13G) and institutional ownership (Form 13F). Insider and 5% data delayed 48 hours.
Insider trading
2 open-market buys totaling $43K and 0 sales totaling - in the last 180 days.
Insider buys
| Score | Ticker | Company | Insider | Role | Trade date | Value | Holding + | Cluster |
|---|---|---|---|---|---|---|---|---|
| 41 | VRXA | Veraxa Biotech AG - Post de-SPAC | Ziegler Christoph Samuel | Director | 2026-10-20 | $33K | 378% | |
| 19 | VRXA | Veraxa Biotech AG | Hosseinion Warren | Director | 2026-09-10 | $10K | 1% |
Get new insider and activist filings the morning after: daily alerts. Not investment advice.